Latest news with #Volition
Yahoo
a day ago
- Business
- Yahoo
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in Japan. AMAMS 2025 is taking place in Thailand. Commenting on the results Dr Sato said: "The Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool, particularly for differentiating between benign and malignant conditions such as Canine Chronic Enteropathy and Gastrointestinal Lymphoma." Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, added: "We are delighted that leading veterinarian Dr Sato has adopted the Nu.Q® Vet Cancer Test in Japan, and not only researching, but publishing specific use cases. We believe this will further raise the awareness of the test and drive wider adoption." The presentations: Title: "Diagnostic Utility of Plasma Nucleosome Concentration in Differentiating Canine Chronic Enteropathy from Gastrointestinal Lymphoma" Presenter: Kentaro NabeshimaDate and Time: Thursday, June 5, 2025, 1:40PM – 1:50PM (ICT)Venue: Room 108Key Conclusion: Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool for distinguishing CE from GIL, with particularly high levels observed in medium-to-large cell "Evaluation of Plasma Nucleosome Concentrations as a Biomarker for Canine Nasal Tumors"Presenter: Chihoko TakahashiDate and Time: Thursday, June 5, 2025, 3:30PM – 3:40PM (ICT)Venue: Room 108 About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries:Louise Batchelor, Volition, mediarelations@ +44 (0)7557 774620 Investor Relations:Jeremy Feffer, LifeSci Advisors, jfeffer@ +1-212-915-2568 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. View original content: SOURCE VolitionRx Limited Sign in to access your portfolio
Yahoo
19-05-2025
- Health
- Yahoo
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer. Frederic Wuilque, Vice President, Global Products, said: "This is an essential step in the development of Nu.Q® products for cats, our third species. This opens up the potential for cancer screening and monitoring in cats, representing a significant annual commercial opportunity for Volition. There are more than 60 million cats in the U.S. alone, 25% of which are "senior" cats and therefore suitable for an annual check1. "This important study confirms that H3.1 nucleosomes can be successfully quantified from blood obtained from healthy cats and presents data regarding an optimal collection and processing protocol. Additionally, it supports the use of EDTA tubes when collecting samples for nucleosome testing in cats. "Our first target product is for feline lymphoma, the most common cause of cancer in cats2. We are delighted to have completed the pre-analytics work for feline and confirm that the enrolment for patients for our clinical study for the detection of feline lymphoma has been underway for several months. We look forward to presenting the findings of our Nu.Q® Vet assay in this much needed area upon study completion." About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries:Louise Batchelor, Volition, mediarelations@ +44 (0)7557 774620 Investor Relations:Jeremy Feffer, LifeSci Advisors, jfeffer@ +1-212-915-2568 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. 1. Data on File. Volition Total Accessible Market Model. 2. Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019. View original content: SOURCE VolitionRx Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Entertainment
- Yahoo
Drummer Chris Adler Opens Up on What Led to Firing from Lamb of God
The post Drummer Chris Adler Opens Up on What Led to Firing from Lamb of God appeared first on Consequence. Chris Adler is considered one of the premier drummers of modern metal, so his firing from Lamb of God in 2019 came as a surprise to longtime fans. Six years later, Adler has finally opened up about what led to his ousting from the band that he co-founded in 1994. In the year leading up to his ouster, Adler had been sitting out shows after a motorcycle accident that shattered his collarbone and right shoulder. Art Cruz was called in to fill in on Lamb of God's tour dates, and eventually was named Lamb of God's permanent drummer upon Adler's firing from the band in July 2019. As it turns out, Adler was suffering from a condition musician's dystonia, which hampered his ability to play drums, even before the motorcycle accident. Around that same time, he had also joined Megadeth for their Grammy-winning 2016 album Dystopia, a few years after he had contributed to Protest the Hero's 2013 LP 'Volition.' The drummer feels that his limited physical ability and the collaborations with other bands led to tension between him and his bandmates, noting in the new interview with Loaded Radio that he was unceremoniously fired by e-mail. 'Dystonia is basically a neurological condition where the nerve that controls the movement of any particular body part basically deteriorates to the point where that motion becomes impossible,' explained Adler (as transcribed by Blabbermouth). 'So people that repeat the same repetitive motion for decades at a time, this happens to them. It happens a lot to golfers, quarterbacks, first-chair violinists, people that just practice the hell out of what they're doing. And this happened to me with my right foot. So I would be playing a song, and my foot, when I intended it to depress the pedal, would shoot off to the side or shoot back. And that was at the point where I was coming off stage just so depressed with my performance.' He continued, 'I think the band was very frustrated with my performance. I did give them the medical paperwork: 'Here's what it is. Here's what we can do. There's just a couple songs that are really aggravating this. The rest I can get through, if you're willing to change 'em.' I think at the time I had also joined Megadeth, so tensions were really high. And we were never like the most functional group of people traveling around the world, if you know anything about the band. So, whoever was not in the room was basically getting picked on.' Adler further noted, 'I think the combination of things got to the point where they didn't wanna deal with it and I wasn't happy with my performances, so that kind of stopped the train. It was one of those e-mails, 'service is no longer required' kind of thing, and that was devastating, 'cause I felt like it was my baby, it was my project and I put my life into it.' After a couple years of intense physical therapy, Adler was back playing the drums again, and he has since formed the band Firstborne with guitarist Myrone and vocalist Girish. The band will release its debut album, Lucky, on July 18th (pre-order here). See Chris Adler's full interview with Loaded Radio and watch the video for Firstborne's recent single 'Wake Up' below. Popular Posts Beyoncé Hit with Cease and Desist Letter Over Video of Her Picking Up Sphere Ghost Become First Hard Rock Act to Go No. 1 on Billboard in Four Years Lady Gaga Plays Biggest Show of Career for 2 Million People at Copacabana Beach Stephen King's The Long Walk Movie Gets Long-Awaited Trailer: Watch The Rehearsal's Latest Episode Had Us Literally Screaming at the Screen Trump Signs Executive Order to End Federal Funding of NPR, PBS Subscribe to Consequence's email digest and get the latest breaking news in music, film, and television, tour updates, access to exclusive giveaways, and more straight to your inbox.
